Outcomes of Vibegron Add-on Therapy in Men With Persistent Storage Symptoms After Receiving Alpha 1-Blocker or Phosphodiesterase 5 Inhibitor
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Urology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of Vibegron Add-on Therapy in Men With Persistent Storage Symptoms After Receiving Alpha 1-Blocker or Phosphodiesterase 5 Inhibitor: A Preliminary Study
Urology 2021 Jan 21;[EPub Ahead of Print], K Ishikawa, A Tsujimura, M Miyoshi, Y Miyoshi, T Ogasa, I Hiramatsu, Y Uesaka, T Nozaki, M Shirai, I Mitsuhashi, S Sugimura, T Mizuno, K Noto, Y Shigeta, S Honda, S Iwata, S HorieFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.